For patients with chronic obstructive pulmonary disorder (COPD), long-term inhaled corticosteroid (ICS) treatment is ...

Significantly greater composite adverse outcome rates seen for long- vs short-term inhaled corticosteroid use for prevalent, inception cohorts. HealthDay News — For patients with chronic ...

Poor treatment of asthma and COPD puts a huge burden on the NHS. For example, £1 billion is spent on asthma treatment in the UK each year and represents 60,000 to 65,000 hospital admissions. In ...

Medically reviewed by Sanja Jelic, MD Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory (lung) ...

The global respiratory inhaler devices market is on the cusp of significant transformation over the next decade, driven by a rising incidence of respiratory diseases, technological advancements, and ...

The Hailie Smartinhaler device has also been cleared for use with inhalers from other manufacturers ... directly to patients with asthma and COPD under a 510(k) over-the-counter clearance.

Dupixent (dupilumab) is available in Japan in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available ...

This profile has not been claimed by the company. See reviews below to learn more or submit your own review. ProAir HFA Inhalers provides respiratory relief of bronchospasm and wheezing through ...

The FDA is poised to issue a final decision on the approval and marketing of Yutrepia, an inhaled dry powder formulation of ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...